Intrinsiqq
Janux Therapeutics Inc. logo

Janux Therapeutics Inc.

JANX

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$982M
EPS-$1.64
P/E-9.79
P/FCF-23.42
EV/EBITDA-0.22
FCF Yield–
Div. Yield–
Net Debt/FCF22.7x
Janux Therapeutics Inc. intrinsic value
52-Week Range
$12.18$34.74

Profitability & Returns

Revenue (TTM)

$24M

▼ -5.6% YoY

Net Income (TTM)

-$103M

▼ -64.7% YoY

Op. Margin

-598.15%

▼ -643.1pp YoY

ROIC

-11.66%

▼ -1.3pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$42M

▼ -88.5% YoY

Op. Cash Flow (TTM)

-$41M

▼ -87.7% YoY

Net Debt

-$950M

Net Cash Position

Cash & Equiv.

$971M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with JANX

CompareIntrinsic value
BGMBGM Group Ltd.
$9.00-5.66%26
ZYBTZhengye Biotechnology Holding Ltd.
$1.38+0.73%9
STOKStoke Therapeutics Inc.
$26.07-5.03%25
SCYXScynexis, Inc.
$3.30-14.06%40
EVFMEvofem Biosciences Inc.
$0.01+1.67%15
FHTXFoghorn Therapeutics Inc.
$1.91-9.29%40
SLGLSol-Gel Technologies Ltd.
$63.01-4.53%65
JAGXJaguar Health, Inc.
$0.41-18.44%40

Held by ETFs

JANX is in 26 US ETFs. The largest of them, with JANX's weight in each:

Janux Therapeutics (JANX) in four numbers

Fair value (revenue)
$3.66
Price $16.06 is 339% above it.
Intrinsic Value
Quality score
40/100
Best check: revenue growth, 29.2%. Weakest: return on capital, -11.7%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-9.79
Negative: a loss over the last twelve months. Price to free cash flow -23.42.
Financials

Questions about Janux Therapeutics

Is Janux Therapeutics (JANX) overvalued?

At $16.06, Janux Therapeutics' price is 339% above the $3.66 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Janux Therapeutics' fair value?

Intrinsiqq's calculator puts Janux Therapeutics' fair value at $3.66 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 15, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $2.74. Every input can be changed on the Intrinsic Value tab.

Is Janux Therapeutics a high-quality business?

Janux Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 29.2%, and its weakest is return on capital at -11.7%. The Quality tab shows every check against its target.

Does Janux Therapeutics (JANX) pay a dividend?

No. Janux Therapeutics (JANX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 4 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 5 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in JANX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing JANX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.